Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Delays fail to Quell Treg interest
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
Spybiotech seeks new vaccines
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.